Objective responses and stable disease in patients with immunotherapy refractory advanced malignant melanoma

This study presented at ESMO 2024 tested LOAd703, a viral vector combined with atezolizumab, in advanced melanoma patients resistant to PD-1/PD-L1 treatments. The trial involved patients with stage IV melanoma who had not responded to prior PD-1/PD-L1 treatments. The results showed that the treatment induced both local and systemic immune responses, potentially re-sensitizing patients to checkpoint inhibitors.